The influence of host factors and immunogenetics on lymphocyte responses to Hepagene® vaccination

Vaccine

Volumn 17, Issue 11-12, 1999, Pages 1329-1337

  McDermott, A B ^a   Madrigal, J A ^a   Sabin, C A ^a   Zuckerman, J N ^a   Cohen, S B A ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

HBsAg; Hepatitis B vaccination; Pre S

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HLA DQ ANTIGEN; HLA DR ANTIGEN; RECOMBINANT HEPATITIS B VACCINE;

ADULT; AGE; AGED; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; FEMALE; GENOTYPE; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOGENETICS; IMMUNOPROPHYLAXIS; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEROCONVERSION; SEX DIFFERENCE; TREATMENT OUTCOME; VACCINATION;

ADULT; AGE FACTORS; AGED; ANTIBODY FORMATION; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; IMMUNOGENETICS; KINETICS; LYMPHOCYTES; MALE; MIDDLE AGED; SEX FACTORS; T-LYMPHOCYTES;

EID: 0033577345     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00389-2     Document Type: Article

References (42)

1. Chang M.H., Chen C.J., Lai M.S., Hsu H.M., Wu T.C., Kong M.S., Liang D.C., Shau W.Y., Chen D.S. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. New England Journal of Medicine. 336:1997;1855-1859.
2. Hadler S.C., Francis D.P., Maynard J.E., Thompson S.E., Judson F.N., Echenberg D.F., Ostrow D.G., O'Malley P., Penley K., Altman N., Braff E.H., Shipman G.F., Coleman P.J., Mandel E.J. Long term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. New England Journal of Medicine. 315:1986;209-215.
3. Jilg W., Schmidt M., Deinhardt F. Immune response to hepatitis B revaccination. Journal of Medical Virology. 24:1988;377-384.
4. Westmoreland D., Player V., Heap D.C., Hammond A. Immunisation against hepatitis B-what can we expect? Epidemiology and Infection. 104:1990;499-509.
5. Jilg W., Schmidt M., Deinhardt F. Four-year experience with a recombinant hepatitis B vaccine. Infection. 17:1989;70-76.
6. Craven D.E., Awdeh Z., Kunches L.M., Yunis E.J., Dienstag J.L., Weener B.G., Polk B.F., Snydman D.R., Platt R., Crumpacker C.S., Grady G.S., Alper C.A. Nonresposiveness to hepatitis B vaccine in health care workers. Annals of Internal Medicine. 105:1986;356-360.
7. Watanabe H., Okumura M., Hirayama K., Sasazuki T. HLA-Bw54-DR4-DRw53-DQw4 haplotype controls nonresponsiveness to hepatitis-B surface antigen via CD8-positive suppressor T-cells. Tissue Antigens. 36:1990;69-74.
8. Hatae K., Kimura A., Okubo R., Watanabe H., Erlich H.A., Ueda K., Nishimura Y., Sasazuki T. Genetic control of nonresponsiveness to hepatitis B virus vaccine by an extended HLA haplotype. European Journal of Immunology. 22:1992;1899-1905.
9. Hsu L.C., Lin S.R., Hsu H.M., Chao W.H., Hsieh J.T., Wang M.C., Lu C.F., Chang Y., Ho M.S. Ethnic differences in immune responses to hepatitis B vaccine. American Journal of Epidemiology. 143:1996;718-724.
10. Milich D.R., Thornton G.B., Neurath A.R., Kent S.B., Tiollais M.L., Chisari F.V. Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science. 228:1985;1195-1198.
11. Milich D.R., McLachlan A., Chisari F.V., Kent S.B., Thorton G.B. Immune response to the pre-S(1) region of the hepatitis B surface antigen (HBsAg): a pre-S(1)-specific T-cell response can bypass nonresponsiveness to the pre-S(2) and S regions of HBsAg. Journal of Immunology. 137:1986;315-322.
12. Zuckerman J.N., Sabin C., Craig F.M., Williams A., Zuckerman A.J. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose response study. BMJ. 314:1997;329-333.
13. McDermott A.B., Zuckerman J.N., Sabin C.A., Marsh S.G.E., Madrigal J.A. Contribution of human leukocyte antigens to the antibody response to hepatitis B vaccination. Tissue Antigens. 50:1997;8-14.
14. Courouce A.M., Laplanche A., Benhamou E., Jungers P. Long-term efficiency of hepatitis B vaccine in healthy adults. In: Zuckerman A.J., editor. Viral hepatitis and liver disease. New York: Alan R. Liss, 1988. p. 1002-5.
15. Whittle H.C., Maine N., Pilkington J., Mendy M., Fortuin M., Bunn J., Allison L., Howard C., Hall A.J. Long term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet. 345:1995;1089-1092.
16. Stevens C.E., Alter H.J., Taylor P.E., Zaug E.A., Harley E.J., Szmuness W. Hepatitis B vaccine in patients receiving haemodialysis: immunogenicity and efficacy. New England Journal of Medicine. 311:1984;496-501.
17. Dahl-Hansen E., Siebke J.C., Froland S.S., Degre M. Immunogenicity of yeast-derived hepatitis B vaccine from two different producers. Epidemiol Infect. 104:1990;143-149. published erratum appears in Epidemiol Infect 1991 Apr; 106(2): 421.
18. Bock H.L., Kruppenbacher J., Sanger R., Hobel W., Clemens R., Jilg W. Immunogenicity of a recombinant hepatitis B vaccine in adults. Archives of Internal Medicine. 156:1996;2226-2231.
19. Payton C.D., Scarisbrick D.A., Sikotra S., Flower A.J. Vaccination against hepatitis B: comparison of intradermal and intramuscular administration of plasma derived and recombinant vaccines. Epidemiol. Infect. 110:1993;177-180.
20. Struve J., Aronson B., Frenning B., Forsgren M., Weiland O. Response to a booster dose 18 months after low dose anti-HBs response (10-99 IU/l) to three doses of intradermally or intramuscularly administered recombinant hepatitis B vaccine. Infection. 23:1995;42-45.
21. Margolis H.S., Presson A.C. Host factors related to poor immunogenicity of hepatitis B vaccine in adults. JAMA. 270:1993;2971-2972.
22. Alper C.A., Kruskall M.S., Marcus-Bagley D., Craven D.E., Katz A.J., Brink S.J., Dienstag J.L., Awdeh Z., Yunis E.J. Genetic prediction of nonresponse to hepatitis B vaccine. New England Journal of Medicine. 321:1989;708-712.
23. Kruskall M.S., Alper C.A., Awdeh Z., Yunis E.J., Marcus-Bagley D. The immune response to hepatitis B vaccine in humans: inheritance patterns in families. J. Exp. Med. 175:1992;495-502.
24. Roome A.J., Walsh S.J., Cartter M.L., Hadler J.L. Hepatitis B vaccine responsiveness in Conneticut public saftey personnel. JAMA. 270:1993;2931-2934.
25. Rumi M., Colombo M., Romeo R., Boschini A., Zanetti A., Gringeri A., Mannucci P.M. Suboptimal response to hepatitis B vaccine in drug abusers. Archives of Internal Medicine. 151:1998;574-577.
26. Taylor P.E., Stevens C.E. Persistence of antibody to hepatitis B surface antigen after vaccination with hepatitis B vaccine. In: Zuckerman A.J., editor. Viral Hepatitis and Liver Disease. New York: Alan R. Liss, 1988. p. 995-7.
27. Nommensen F.E., Go S.T., Maclaren D.M. Half life of HBs antibody affter hepatitis B vaccination: an aid to timing of booster vaccination. Lancet. 2:1989;847-849.
28. Leclerc C., Sedlik C., Lo-Man R., Charlot B., Rojas M., Deriaud E. Stimulation of a memory B-cell response does not require primed helper T-cells. European Journal of Immunology. 25:1995;2533-2538.
29. Bocher W.O., Herzog-Hauff S., Herr W., Heermann K., Gerken G., Meyer Z., Buschenfelde K.H., Lohr H.F. Regulation of the neutralizing antihepatitis B surface (HBs) antibody response in vitro in HBs vaccine recipients and patients with acute or chronic hepatitis B virus (HBV) infection. Clinical and Experimental Immunology. 105:1996;52-58.
30. Clements M.L., Miskovsky E., Davidson M., Cupps T., Kumwenda N., Sandman L., West D., Hesley T., Ioli V., Miller W.et al. Effect of age on the immunogenicity of yeast recombinant hepatitis B vaccines containing surface antigen (S) or pre-S2+S antigens. Journal of Infectious Diseases. 170:1994;510-516.
31. Bertino J.S. Jr., Tirrell P., Greenberg R.N., Keyserling H.L., Poland G.A., Gump D., Kumar M.L., Ramsey K. A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S1 and pre-S2 particles for revaccination of healthy adult nonresponders. Journal of Infectious Diseases. 175:1997;678-681.
32. McDermott A.B., Cohen S.B.A., Zuckerman J.N., Madrigal J.A. Human leukocyte antigens influence the immune response to a pre-S/S hepatitis B vaccine. Vaccine, in press, 1998.
33. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Research. 16:1988;1215-1218.
34. Fagan E.A., Tolley P., Smith H., Peters M.P., Coleman J., Elliot P., Williams R., Eddleston A.L.W.F. Heptitis B vaccine immunogenicity and follow-up including two year booster doses in high risk health personnel in a London teaching hospital. Journal of Medical Virology. 21:1987;49-56.
35. Suzuki H., Iino S., Shiraki K., Akahane Y., Okamoto H., Domoto K., Mishiro S. Safety and efficacy of a recombinant yeast derived pre-S2+S-conatining hepatitis B vaccine (TGP-943): phase 1, 2 and 3 clinical testing. Vaccine. 12:1994;1091-1096.
36. LeMaoult J., Szabo P., Weksler M.E. Effect of age on humoral immunity, selection of the B-cell repertoire and B-cell development. Immunological Reviews. 160:1997;115-126.
37. Degrassi A., Mariani E., Honorati M.C., Roda P., Miniero R., Capelli M., Facchini A. Cellular response and anti-HBs synthesis in vitro after vaccination with yeast-derived recombinant hepatitis vaccine. Vaccine. 10:1992;617-622.
38. Leroux-Roels G., Van Hecke E., Michielsen W., Voet P., Hauser P., Petre J. Correlation between in vivo humoral and in vitro cellular immune responses following immunization with hepatitis B surface antigen (HBsAg) vaccines. Vaccine. 12:1994;812-818.
39. Vingerhoets J., Vanham G., Kestens L., Penne G., Leroux-Roels G., Gigase P. Deficient T-cell responses in nonresponders to hepatitis B vaccination: absence of TH1 cytokine production. Immunology Letters. 39:1994;163-168.
40. Egea E., Iglesias A., Salazar M.et al. The cellular basis for lack of response to hepatitis B vaccine in humans. J. Exp. Med. 173:1991;531-538.
41. Ferrari C., Penna A., Bertoletti A., Cavalli A., Valli A., Schianchi C., Fiaccadori F. The pre-S1 antigen of hepatitis B virus is highly immunogenic at the T-cell level in man. Journal of Clinical Investigation. 84:1989;1314-1319.
42. Bachmann M.F., Kunig T.M., Hengartner H., Zinkernagel R.M. Regulation of IgG titres by the amount persisting of immune-complexed antigen. European Journal of Immunology. 24:1994;2567-2570.